JP2010202664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010202664A5 JP2010202664A5 JP2010130425A JP2010130425A JP2010202664A5 JP 2010202664 A5 JP2010202664 A5 JP 2010202664A5 JP 2010130425 A JP2010130425 A JP 2010130425A JP 2010130425 A JP2010130425 A JP 2010130425A JP 2010202664 A5 JP2010202664 A5 JP 2010202664A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- seq
- amino acid
- patient
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054218 Factor VIII Proteins 0.000 claims 19
- 102000001690 Factor VIII Human genes 0.000 claims 19
- 229960000301 factor viii Drugs 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 230000003480 fibrinolytic effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37635102P | 2002-04-29 | 2002-04-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Division JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010202664A JP2010202664A (ja) | 2010-09-16 |
| JP2010202664A5 true JP2010202664A5 (enExample) | 2011-07-21 |
Family
ID=29401334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Pending JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
| JP2010130425A Pending JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Pending JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8586538B2 (enExample) |
| EP (1) | EP1497330B1 (enExample) |
| JP (2) | JP2005535588A (enExample) |
| AT (1) | ATE463514T1 (enExample) |
| AU (1) | AU2003227687B2 (enExample) |
| CA (1) | CA2484155C (enExample) |
| DE (1) | DE60332011D1 (enExample) |
| DK (1) | DK1497330T3 (enExample) |
| ES (1) | ES2343681T3 (enExample) |
| WO (1) | WO2003093313A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2490280A1 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP1454632A1 (en) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006003183A1 (de) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptide zur blockierung von fviii-inhibitoren |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| JP2009274958A (ja) | 2006-08-31 | 2009-11-26 | Nara Prefecture | 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体 |
| EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| CN102112623A (zh) * | 2008-06-04 | 2011-06-29 | 拜耳医药保健有限公司 | 用于治疗血管性血友病的fviii突变蛋白 |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| JP5394864B2 (ja) * | 2009-09-10 | 2014-01-22 | アスモ株式会社 | モータ |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| EP3466968A1 (en) | 2010-09-15 | 2019-04-10 | Stichting Sanquin Bloedvoorziening | Factor viii variants having a decreased cellular uptake |
| ES2651523T3 (es) | 2012-02-15 | 2018-01-26 | Csl Behring Gmbh | Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| AU2015283822B2 (en) | 2014-07-02 | 2019-10-03 | CSL Behring Lengnau AG | Modified von willebrand factor |
| DK3265483T3 (da) | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modificeret von Willebrand-faktor med forbedret halveringstid |
| SG11201708755WA (en) | 2015-05-22 | 2017-12-28 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| CN107810194B (zh) | 2015-05-22 | 2021-10-08 | 康诺贝林伦瑙有限公司 | 用于制备经修饰的血管性血友病因子的方法 |
| SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
| SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
| AU2017358865A1 (en) | 2016-11-11 | 2019-05-09 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| TW201828975A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Ｃｓｌ貝林重組技能公司 | 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2221567A1 (en) * | 1995-06-12 | 1996-12-27 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Ned Erlandse Rode Kruis | Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation |
| PT1095143E (pt) * | 1998-05-08 | 2008-11-28 | Sanquin Bloedvoorziening | Inibidor para o diagnóstico e tratamento de doentes com hemofilia a |
| CA2349468C (en) * | 1998-11-10 | 2013-07-09 | Baxter Aktiengesellschaft | Factor viii polypeptide having factor viii:c activity |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
-
2003
- 2003-04-28 CA CA2484155A patent/CA2484155C/en not_active Expired - Lifetime
- 2003-04-28 AT AT03725109T patent/ATE463514T1/de active
- 2003-04-28 DK DK03725109.7T patent/DK1497330T3/da active
- 2003-04-28 EP EP03725109A patent/EP1497330B1/en not_active Expired - Lifetime
- 2003-04-28 AU AU2003227687A patent/AU2003227687B2/en not_active Ceased
- 2003-04-28 WO PCT/EP2003/004425 patent/WO2003093313A2/en not_active Ceased
- 2003-04-28 JP JP2004501452A patent/JP2005535588A/ja active Pending
- 2003-04-28 US US10/512,907 patent/US8586538B2/en not_active Expired - Fee Related
- 2003-04-28 ES ES03725109T patent/ES2343681T3/es not_active Expired - Lifetime
- 2003-04-28 DE DE60332011T patent/DE60332011D1/de not_active Expired - Lifetime
-
2010
- 2010-06-07 JP JP2010130425A patent/JP2010202664A/ja active Pending